Welcome. Fixing the formulation issues that caused bisantrene to originally be dropped is exactly what we have done. We know our drug works (it was even approved in France back in the 1980s), it just wasn't easy to use. We have solved this with the new RC220 formulation and we have just completed the cGMP manufacturing last month and we are now completing the non-clinical toxicology testing (due to be finished in June) allowing it to be used in patients in H2 this year.
Bisantrene is a really interesting drug solving a massive problem with exisiting cancer treatments. The clinical history of bisantrene moves the chance of success from the usual 3% for new cancer drugs at Phase 1 to something closer to the 80% success that reformulated drugs achieve. In my opinion successful investment in biotechs is all about minimising risk which is what drew me to RAC in the first place.
Welcome. Fixing the formulation issues that caused bisantrene to...
- There are more pages in this discussion • 339 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.045(2.80%) |
Mkt cap ! $260.3M | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.60 | $1.55 | $94.33K | 60.12K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2000 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 554 | 1 |
View Market Depth
| Last trade - 14.37pm 16/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.56 |
Change
-0.045 ( 1.17 %) |
||||
| Open | High | Low | Volume | ||
| $1.58 | $1.59 | $1.55 | 8174 | ||
| Last updated 14.21pm 16/05/2024 ? | |||||
| RAC (ASX) Chart |